WallStSmart

Alpha Teknova Inc (TKNO)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 35191% more annual revenue ($14.30B vs $40.52M). VTRS leads profitability with a -24.6% profit margin vs -42.6%. VTRS earns a higher WallStSmart Score of 50/100 (C-).

TKNO

Avoid

31

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 5.0Quality: 7.0
Piotroski: 5/9Altman Z: 0.16

VTRS

Buy

50

out of 100

Grade: C-

Growth: 3.3Profit: 3.5Value: 6.7Quality: 5.5
Piotroski: 4/9Altman Z: 0.80

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

TKNO2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.229/10

Conservative balance sheet, low leverage

Price/BookValuation
2.4x8/10

Reasonable price relative to book value

VTRS2 strengths · Avg: 10.0/10
PEG RatioValuation
0.1410/10

Growing faster than its price suggests

Price/BookValuation
1.1x10/10

Reasonable price relative to book value

Areas to Watch

TKNO4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$159.69M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-22.8%2/10

ROE of -22.8% — below average capital efficiency

Free Cash FlowQuality
$-710,0002/10

Negative free cash flow — burning cash

VTRS4 concerns · Avg: 1.8/10
Return on EquityProfitability
-21.1%2/10

ROE of -21.1% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.802/10

Distress zone — elevated risk

Profit MarginProfitability
-24.6%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : TKNO

The strongest argument for TKNO centers on Debt/Equity, Price/Book.

Bull Case : VTRS

The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.

Bear Case : TKNO

The primary concerns for TKNO are EPS Growth, Market Cap, Return on Equity.

Bear Case : VTRS

The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.

Key Dynamics to Monitor

VTRS carries more volatility with a beta of 0.80 — expect wider price swings.

TKNO is growing revenue faster at 7.8% — sustainability is the question.

VTRS generates stronger free cash flow (551M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VTRS scores higher overall (50/100 vs 31/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alpha Teknova Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Alpha Teknova Inc (TKNO) is a leading provider of synthetic biology solutions, specializing in high-quality biological reagents and supplements essential for life sciences research and biomanufacturing. The company addresses critical needs across key sectors, such as vaccine development, cell and gene therapy, and diagnostic testing, while maintaining a steadfast commitment to quality and customer service excellence. With a robust foundation in biotechnology and a focus on innovation, Alpha Teknova is well-positioned to capitalize on the expanding opportunities within the life sciences market, fostering growth and delivering value to its investors.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?